ADC Therapeutics
Jay Feingold has a background in pharmaceuticals and medical affairs. Jay was the Chief Medical Officer and Senior Vice President at ADC Therapeutics since September 2014. Before that, they held the position of Vice President Medical Affairs at Daiichi Sankyo, Inc. from January 2010 to August 2014. Prior to that, they were a Vice President at Wyeth from 2000 to 2010.
Jay Feingold completed their Bachelor of Science (B.S.) degree in Biology, General at Stony Brook University, although the specific start and end years for this period are not provided. Subsequently, they pursued further education at Albert Einstein College of Medicine and obtained both an MD and PhD in Molecular Biology, from 1979 to 1986.
This person is not in any offices
ADC Therapeutics
2 followers
ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.